Intranasal Delivery--modification of Drug Metabolism and Brain Disposition

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2010 Apr 8

PMID 20372990

Citations 13

Authors

Yin Cheong Wong

Zhong Zuo

Affiliations

Soon will be listed here.

Abstract

Intranasal route continues to be one of the main focuses of drug delivery research. Although it is generally perceived that the nasal route could avoid the first-pass metabolism in liver and gastrointestinal tract, the role of metabolic conversions in systemic and brain-targeted deliveries of the parent compounds and their metabolites should not be underestimated. In this commentary, metabolite formations after intranasal and other routes of administration are compared. Also, the disposition of metabolites in plasma and brain after nasal administrations of parent drugs, prodrugs and preformed metabolites will be discussed. The importance and implications of metabolism for future nasal drug development are highlighted.

Citing Articles

Pharmacokinetic Study of Fingolimod Nasal Films Administered via Nose-to-Brain Route in C57BL/6 J Mice as Potential Treatment for Multiple Sclerosis.

Papakyriakopoulou P, Balafas E, Kostomitsopoulos N, Rekkas D, Dev K, Valsami G Pharm Res. 2024; 41(10):1951-1963.

PMID: 39470941 DOI: 10.1007/s11095-024-03745-8.

Enhanced Delivery of Neuroactive Drugs via Nasal Delivery with a Self-Healing Supramolecular Gel.

Wang J, Rodrigo A, Patterson A, Hawkins K, Aly M, Sun J Adv Sci (Weinh). 2021; 8(14):e2101058.

PMID: 34029010 PMC: 8292877. DOI: 10.1002/advs.202101058.

Non-Invasive Strategies for Nose-to-Brain Drug Delivery.

Trevino J, Quispe R, Khan F, Novak V J Clin Trials. 2021; 10(7).

PMID: 33505777 PMC: 7836101.

Alzheimer's Disease: An Overview of Major Hypotheses and Therapeutic Options in Nanotechnology.

Agarwal M, Alam M, Haider M, Malik M, Kim D Nanomaterials (Basel). 2021; 11(1).

PMID: 33383712 PMC: 7823376. DOI: 10.3390/nano11010059.

Pharmacokinetics, absolute bioavailability and tolerability of ketamine after intranasal administration to dexmedetomidine sedated dogs.

Vlerick L, Devreese M, Peremans K, Dockx R, Croubels S, Duchateau L PLoS One. 2020; 15(1):e0227762.

PMID: 31929589 PMC: 6957157. DOI: 10.1371/journal.pone.0227762.

References

Illum L . Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci. 2000; 11(1):1-18. DOI: 10.1016/s0928-0987(00)00087-7. View

Prueksaritanont T, Lin J, Baillie T . Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites. Toxicol Appl Pharmacol. 2006; 217(2):143-52. DOI: 10.1016/j.taap.2006.08.009. View

Dhuria S, Hanson L, Frey 2nd W . Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci. 2009; 99(4):1654-73. DOI: 10.1002/jps.21924. View

Faraj J, Hussain A, Aramaki Y, Iseki K, Kagoshima M, DITTERT L . Mechanism of nasal absorption of drugs. III: Nasal absorption of leucine enkephalin. J Pharm Sci. 1990; 79(8):698-702. DOI: 10.1002/jps.2600790810. View

Lesko L, Atkinson Jr A . Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol. 2001; 41:347-66. DOI: 10.1146/annurev.pharmtox.41.1.347. View

Fishburn C . The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J Pharm Sci. 2008; 97(10):4167-83. DOI: 10.1002/jps.21278. View

Pavan B, Dalpiaz A, Ciliberti N, Biondi C, Manfredini S, Vertuani S . Progress in drug delivery to the central nervous system by the prodrug approach. Molecules. 2008; 13(5):1035-65. PMC: 6245073. DOI: 10.3390/molecules13051035. View

Fura A . Role of pharmacologically active metabolites in drug discovery and development. Drug Discov Today. 2006; 11(3-4):133-42. DOI: 10.1016/S1359-6446(05)03681-0. View

Werner U, Kissel T . Development of a human nasal epithelial cell culture model and its suitability for transport and metabolism studies under in vitro conditions. Pharm Res. 1995; 12(4):565-71. DOI: 10.1023/a:1016210231121. View

10.

Kao H, Traboulsi A, Itoh S, Dittert L, Hussain A . Enhancement of the systemic and CNS specific delivery of L-dopa by the nasal administration of its water soluble prodrugs. Pharm Res. 2000; 17(8):978-84. DOI: 10.1023/a:1007583422634. View

11.

Kashi S, Lee V . Enkephalin hydrolysis in homogenates of various absorptive mucosae of the albino rabbit: similarities in rates and involvement of aminopeptidases. Life Sci. 1986; 38(22):2019-28. DOI: 10.1016/0024-3205(86)90150-5. View

12.

Dale O, Hjortkjaer R, Kharasch E . Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand. 2002; 46(7):759-70. DOI: 10.1034/j.1399-6576.2002.460702.x. View

13.

Al-Ghananeem A, Traboulsi A, Dittert L, Hussain A . Targeted brain delivery of 17 beta-estradiol via nasally administered water soluble prodrugs. AAPS PharmSciTech. 2003; 3(1):E5. PMC: 2750252. DOI: 10.1208/pt030105. View

14.

Harris A, Ohlin M, Lethagen S, Nilsson I . Effects of concentration and volume on nasal bioavailability and biological response to desmopressin. J Pharm Sci. 1988; 77(4):337-9. DOI: 10.1002/jps.2600770412. View

15.

Yates R, Nairn K, Dixon R, Seaber E . Preliminary studies of the pharmacokinetics and tolerability of zolmitriptan nasal spray in healthy volunteers. J Clin Pharmacol. 2002; 42(11):1237-43. DOI: 10.1177/009127002762491325. View

16.

Na D, Youn Y, Park E, Lee J, Cho O, Lee K . Stability of PEGylated salmon calcitonin in nasal mucosa. J Pharm Sci. 2004; 93(2):256-61. DOI: 10.1002/jps.10537. View

17.

Greenblatt D, Ehrenberg B, Gunderman J, Scavone J, Tai N, Harmatz J . Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam. J Pharmacol Exp Ther. 1989; 250(1):134-40. View

18.

Graff C, Pollack G . P-Glycoprotein attenuates brain uptake of substrates after nasal instillation. Pharm Res. 2003; 20(8):1225-30. DOI: 10.1023/a:1025053115583. View

19.

Wang H, Hussain A, Wedlund P . Nipecotic acid: systemic availability and brain delivery after nasal administration of nipecotic acid and n-butyl nipecotate to rats. Pharm Res. 2005; 22(4):556-62. DOI: 10.1007/s11095-005-2491-0. View

20.

Rook E, Huitema A, van den Brink W, van Ree J, Beijnen J . Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature. Curr Clin Pharmacol. 2008; 1(1):109-18. DOI: 10.2174/157488406775268219. View